Child Psychiatry for Adult Psychiatrists

In the second positive phase 3 trial of lumateperone (Caplyta) for bipolar mania, participants saw improved manic symptoms vs placebo as early as day 3.

Reach Out and Read serves 4.8 million children, but 23% of parents at 3 centers reported clinician modeling, tied to the greatest home literacy gains.

New data shows cannabis dominates teens’ substance-related ER visits, often with alcohol or stimulants, urging better screening and intervention for psychosis, vomiting.

Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans.

Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.